FIELD: medicine; ophthalmology.
SUBSTANCE: group of inventions is intended for treating adenoviral eye infection. That is ensured by using the RNase of the RNase A superfamily by local administration of RNase to the eye. RNase of the RNase A superfamily is also provided in preparing the drug for local treatment of adenoviral eye infection. In another embodiment, a method of treating an adenoviral eye infection is provided, comprising a step of local administration to the eye of a therapeutically effective amount of RNase of the RNase A superfamily.
EFFECT: using the group of inventions enables providing higher clinical effectiveness in adenoviral eye infection.
42 cl, 4 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| RECOMBINANT MODIFIED FIBROBLAST GROWTH FACTORS AND THEIR THERAPEUTIC USE | 2018 |
|
RU2811435C2 |
| AFRICAN SWINE FEVER VACCINE | 2020 |
|
RU2819672C2 |
| VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
| VACCINE COMPOSITION FOR TREATMENT OF CANCER | 2018 |
|
RU2782261C2 |
| ADENOVIRUSES AND METHODS FOR ADENOVIRUS APPLICATION | 2019 |
|
RU2782528C1 |
| MUTATIONS IN OAS1 GENES | 2006 |
|
RU2465328C2 |
| CHIMERIC PROTEIN, A SYNTHETIC DNA WHICH CODES SAID PROTEIN, AN EXPRESSION VECTOR, A SYNTHETIC DNA PRODUCING STRAIN AND A METHOD OF PRODUCING PLASMID DNA | 2016 |
|
RU2736472C2 |
